Catalyst Wire Dossier Catalyst Wire Dossier

Pembrolizumab (Keytruda)

pembrolizumab · Merck & Co
Drug timelines are a Plus or Pro feature.

53 regulatory and trial events tracked for Pembrolizumab (Keytruda), covering 2020-03-20 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer [Phase 3]

See pricing